| |
Thursday, March 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinarto learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now.
|
|
| By Andrea Park During a hearing that lasted just under 90 minutes on Friday, Judge Edward Davila stopped short of offering a definitive ruling on Elizabeth Holmes' dual bids to stay out of prison while awaiting an appeal and to avoid paying restitution for her four felony convictions. |
|
|
|
By Zoey Becker After a late January round of layoffs affecting 300, Amgen axed another 450 jobs citing drug pressure and inflation. The cuts come after an investor lawsuit alleging the company hid a massive $10.7 billion tax bill from its investors. |
By Nick Paul Taylor For Sangamo, last week is probably one to forget. Late on Friday, the gene-based therapy biotech revealed it had lost two partners in quick succession, with Biogen and Novartis walking away from partnerships collectively worth billions of dollars in milestones within days of each other. |
By Teresa Carey This week on "The Top Line," we discuss Fierce Medtech’s annual Fierce 15 report and startups that made the cut. We also cover Illumina and Carl Icahn's proxy battle and more of this week's top headlines. |
|
Tuesday, April 4, 2023 | 10am ET / 7am PT Life sciences leaders are reporting that investments in cloud technology are opening new doors for enhanced productivity, improved time-to-insights, and more. Join this one-hour deep diveinto the latest solutions and strategies for successfully accelerating innovation while optimizing costs. Register now.
|
|
By Andrea Park Since its humble beginnings back in 2012, the Fierce 15 has made a point of spotlighting the most exciting startups in medtech—those not only challenging the limits of both the tech and healthcare industries but also making real progress toward their lofty goals. The companies on this year’s list—which kicks off the second decade of Fierce Medtech’s Fierce 15—are setting the bar even higher. |
By Annalee Armstrong $100 million for Rapport Therapeutics. $112 million for Noema Pharma. $108 million for Bicara Therapeutics. The megaround has come roaring back in the past few weeks, but is biotech really healing? |
By Ben Adams If it’s March, it must be #FierceMadness, Fierce Pharma Marketing’s annual take on the March Madness NCAA basketball tournament and bracket mania—with a pharma twist. |
By Angus Liu In what’s expected to be one of AbbVie’s “biggest new product launches” in the coming years, the company has hit a snag. The FDA rejected AbbVie’s Parkinson’s disease combo therapy over questions about its delivery pump. |
By Andrea Park Health tech investors and companies shopping for a new M&A target this year may want to check out the produce section. |
By Nick Paul Taylor A sudden change of heart at the FDA has sunk Sarepta’s stock. Two weeks after saying the FDA would assess its gene therapy without an advisory committee meeting, Sarepta has revealed the agency will now convene experts to dig into the data on its Duchenne muscular dystrophy (DMD) submission. |
By Angus Liu Under David Ricks’ leadership, Eli Lilly’s stock price reached a record high in 2022. But the CEO’s pay decreased slightly last year. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
By Andrea Park The letter follows an early November inspection of one of Olympus’ Tokyo facilities, during which the FDA concluded that some of the company's endoscopes and endoscope accessories are “adulterated” due to improper manufacturing practices. |
By Fraiser Kansteiner Genentech is winding down operations at its production facility in South San Francisco, the company told Fierce Pharma. The site wrapped up its final production runs several weeks ago and is now in the decommissioning phase, which will take some six to 12 months. |
By Nick Paul Taylor Astellas Pharma’s zolbetuximab has gone two for two, chalking up a second phase 3 win to cement its status as the front-runner in the race to deliver a drug against one of the hottest targets in cancer today. |
By Andrea Park The FDA cleared a pair of tests this week both aimed specifically at improving diagnoses of women’s health conditions. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss Fierce Medtech’s annual Fierce 15 report and startups that made the cut. We also cover Illumina and Carl Icahn's proxy battle and more of this week's top headlines. |
|
|---|
|
|
| ResearchThe current real-world safety reporting process is too burdensome for most HCPs – how can technology help? Sponsored by: Veradigm |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperDownload Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success. Sponsored by: Herspiegel Consulting |
| WhitepaperLearn how HCP statements influence patient decisions Sponsored by: ZoomRx - HCP-Patient Dialogue Research |
| Executive SummaryRead about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines. Sponsored by: Twist Bioscience |
| Whitepaper Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
| eBook Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including large molecules and novel indications. Sponsored By: Catalent |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
